Multi-strategy investing
Investing in healthcare and biotechnology across Asia.
ALX is a multi-strategy investment firm focused on pan-Asian healthcare and biotechnology.
Healthcare
Investing across the healthcare value chain.
Our healthcare strategy targets businesses, assets and development opportunities across Asia. We invest across the healthcare value chain, combining the acquisition and growth of established businesses with the development of new platforms and facilities.
We work with management teams and operating partners to expand capabilities, improve performance and execute strategic growth. Our approach brings together capital, operational expertise and strategic partnerships, with investment structures tailored to each opportunity. We maintain flexibility across business models and stages of development, guided by disciplined capital allocation and strong governance.
Biotechnology
Advancing Asian innovation for global markets
Our biotechnology strategy focuses on companies and therapeutic assets across Asia, with a particular emphasis on China. We seek differentiated science addressing unmet medical needs, with the potential for international development and commercialisation.
We invest in both biotechnology companies and dedicated platforms built around selected therapeutic assets, bringing together rights, capital and specialist expertise to advance individual programmes. Scientific and clinical diligence is complemented by an assessment of intellectual property, development requirements and commercial potential. We pursue value through disciplined development, strategic partnerships and licensing opportunities.
Deeptech special situations
Alongside our core healthcare and biotechnology strategies, we consider select deeptech special situations. We focus on opportunities where business quality, valuation and transaction structure support a compelling investment case.